Literature DB >> 6537833

Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma.

R O Holness, A H Shlossberg, L P Heffernan.   

Abstract

We studied a man with cerebrospinal fluid rhinorrhea due to bromocriptine-induced shrinkage of a prolactin-secreting pituitary tumor. Unlike other reported cases with pituitary tumors and rhinorrhea, our patient never had previous radiotherapy or surgery. The fistula was clearly demonstrated by CT. The original signs included homonymous hemianopia due to a left optic tract compression. Bromocriptine treatment is an invaluable adjunct in long-term management of invasive prolactinomas, but surgical intervention is indicated if a CSF fistula results.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6537833     DOI: 10.1212/wnl.34.1.111

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Authors:  Tomáš Česák; Pavel Poczos; Jaroslav Adamkov; Jiří Náhlovský; Petra Kašparová; Filip Gabalec; Petr Čelakovský; Ondrej Choutka
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

2.  Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases.

Authors:  P Cappabianca; S Lodrini; G Felisati; C Peca; R Cozzi; A Di Sarno; L M Cavallo; S Giombini; A Colao
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

3.  Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma.

Authors:  G Hildebrandt; J Zierski; P Christophis; A Laun; H Schatz; I Lancranjan; N Klug
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Transient intrasellar collection of air during bromocriptine treatment of a prolactinoma.

Authors:  W J Fagel; R E Hekster; S J Smith; J C van der Vijver
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

Review 5.  A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.

Authors:  J Berwaerts; J Verhelst; R Abs; B Appel; C Mahler
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

Review 6.  Current management of prolactinomas.

Authors:  P Nomikos; M Buchfelder; R Fahlbusch
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

7.  Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon.

Authors:  C Confavreux; C Chapuis-Cellier; P Arnaud; O Robert; G Aimard; M Devic
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

8.  Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients.

Authors:  M R O'Gorman; J Oger; L F Kastrukoff
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

9.  Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma.

Authors:  Pratibha Singh; Manish Singh; Goutham Cugati; Ajai Kumar Singh
Journal:  J Hum Reprod Sci       Date:  2011-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.